MCL Literature Feed

This systematic review of brexu-cel for relapsed/refractory MCL reveals conflicting cost-effectiveness conclusions across different countries, highlighting major uncertainties for health systems considering its adoption and reimbursement.

This general review contextualizes CAR T-cell therapy, including its approved use in mantle cell lymphoma, within the broader landscape of cellular therapies, summarizing its efficacy and common toxicities.

This review highlights that TP53-mutated MCL represents a distinct high-risk entity with poor outcomes to chemoimmunotherapy, underscoring the urgent need for novel, non-chemotherapy frontline approaches in these patients.

Reviewing the TRIANGLE trial, this paper argues that adding ibrutinib to frontline induction makes omitting autologous stem cell transplant consolidation a non-inferior, less toxic option for young patients.

This review outlines the clinical landscape and practical application of CAR-T and bispecific antibodies for relapsed/refractory MCL, guiding their integration into practice after targeted therapy failure.

This case report and literature review details the diagnosis and management of central nervous system involvement in MCL, a rare and aggressive manifestation with a poor prognosis.

This case report of non-nodal CNS MCL mimicking autoimmune or paraneoplastic encephalitis highlights the need to consider lymphoma in the differential diagnosis of complex neurological syndromes.

This review details Bortezomib's multiple anti-cancer mechanisms and significant toxicities, highlighting the need for next-generation proteasome inhibitors with better therapeutic windows for treating mantle cell lymphoma.

This review synthesizes the evolution of BTK-targeted therapies, from covalent inhibitors to non-covalent agents and degraders, outlining current treatment paradigms and future combination strategies for frontline and relapsed MCL.

Reviewing AIM and SYMPATICO trials, the ibrutinib-venetoclax combination shows high efficacy in relapsed/refractory MCL, supporting a potential fixed-duration, MRD-guided treatment strategy.

This review summarizes the clinical development and efficacy of BTK inhibitors in MCL, detailing common resistance mutations and outlining future directions for this crucial targeted therapy class.

This preclinical, biophysical study characterizes bortezomib's binding to serum albumin, providing fundamental pharmacokinetic data with no direct clinical implications for treating MCL patients.

The first approval of odronextamab, a CD20xCD3 bispecific antibody, in other lymphomas introduces a promising off-the-shelf, T-cell engaging immunotherapy for potential use in relapsed/refractory MCL.

This review confirms MRD's strong prognostic value in MCL but cautions that technical limitations and the uncertain clinical significance of low-level disease currently prevent its routine use for treatment decisions.

This review summarizes the established efficacy and toxicities of CD19 CAR-T therapy in B-cell lymphomas, including MCL, while highlighting future research directions like novel targets and sequencing with bispecifics.

This case report demonstrates that MCL can cause severe renal failure via both direct infiltration and paraneoplastic glomerulonephritis, underscoring the need for kidney biopsy in unexplained nephropathy.

A rare case of composite MCL and lymphoplasmacytic lymphoma in bone marrow highlights the necessity of advanced diagnostics like NGS and FISH to differentiate from MCL with plasmacytic differentiation.

This retrospective case series strengthens the link between ibrutinib and delayed-onset uveitis, a potentially vision-threatening toxicity that resolves upon drug cessation, highlighting a key clinical management consideration.

Analysis of European MCL Network trial data shows specific gene mutations predict patient outcomes, providing a genetic basis for risk stratification to guide therapy selection beyond clinical scores.

This phase 1 trial establishes the safety and preliminary efficacy of combining the HDAC inhibitor abexinostat with ibrutinib in relapsed/refractory MCL, suggesting a potential new BTKi-based combination strategy.

The polatuzumab-based regimen, Pola-R-mini-CHP, demonstrated efficacy in elderly relapsed/refractory MCL, offering a potential new ADC-chemoimmunotherapy option for this difficult-to-treat population.

Quantitative measurement of Cyclin D1 protein reveals that higher levels are paradoxically associated with better overall survival, establishing a novel, independent prognostic biomarker for MCL risk stratification.

A novel nanostructured lipid carrier (NLC) formulation increased ibrutinib's oral bioavailability by 1.82-fold in a rat model, suggesting a potential strategy to enhance drug delivery and efficacy.

A novel αCD20-EndoP125A antibody fusion protein inhibits MCL growth and dissemination in preclinical models by disrupting tumor-vessel interactions, including angiogenesis, lymphangiogenesis, and vessel co-option.

Real-world, intention-to-treat data from the French DESCAR-T registry confirms brexucabtagene autoleucel efficacy in relapsed/refractory MCL, providing practical outcomes for all patients intended for treatment.

This first case report of concurrent zanubrutinib and radiotherapy demonstrates a manageable safety profile, suggesting BTKi therapy may not require interruption for necessary radiation in MCL patients.

Long-term follow-up after autologous stem cell transplant in MCL is critical for detecting late relapses and managing treatment-related toxicities, guiding post-transplant surveillance strategies.

Malignant effusions, frequently caused by blastoid MCL, are characterized by a T/B cell ratio <1, providing a crucial diagnostic marker from cytological samples.

This large, single-center retrospective study characterizes the aggressive nature and poor outcomes of MCL with cutaneous involvement, providing crucial real-world data for managing this rare presentation.

This meta-analysis quantifies the poor prognosis (median OS ~9 months) for r/r MCL patients post-covalent BTKi treated with standard therapies, highlighting the superior efficacy of brexucabtagene autoleucel.